Membership Directory

Millennium: The Takeda Oncology Company

Category: Drug Development
Phone: (617) 444-3285
Fax: (617) 374-7788
Website: http://www.millennium.com
Location: Cambridge, MA

Founded in early 1993, Millennium Pharmaceuticals, Inc. is a leading biopharmaceutical company, focused on the discovery and development of small molecule, biotherapeutic and predictive medicine products. Millennium applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Mass., Millennium currently employs more than 1,500 people. To accelerate the process of drug discovery and development, Millennium employs industrial-scale genetics, genomics, high-throughput screening and chemistry, predictive ADMET tools, informatics as well as a host of other leading-edge technologies in an integrated science and technology platform. Millennium applies this comprehensive platform to identify genes, elucidate their function, validate targets and develop breakthrough products. Millennium has three key franchise areas: cancer, metabolic diseases, and inflammation. The Company also has significant programs in infectious diseases, cardiovascular diseases and diseases of the central nervous system. In addition, Millennium is the leader in Diagnomic and Pharmacogenomic research programs. Each of these therapeutic areas addresses significant unmet medical needs, and combined, they offer rewarding market opportunities. Within the targeted areas, Millennium is making substantial progress in its clinical development program with six products in clinical trials and more than 20 candidates in late lead development and preclinical testing. Millennium is focused on executing an operational plan that will continue to rapidly move downstream toward commercialization of therapeutic and predictive medicines.

Back to list

Janitronics

EvaluatePharma
 

AT&T